Literature DB >> 20051858

The relevance of reward pathways for schizophrenia.

Hisham Ziauddeen1, Graham K Murray.   

Abstract

PURPOSE OF REVIEW: There has been a resurgence of interest in the field of reward processing in schizophrenia in recent years, aided by insights from functional neuroimaging. We examine how disturbances in reward-related processes relate to the pathophysiology and symptomatology of this disorder. RECENT
FINDINGS: Behavioural and functional neuroimaging studies in psychosis demonstrate impairments in the representation of reward value and in reward-related learning and a failure to motivate behaviour for incentives. These impairments are linked to abnormal mesocorticolimbic and mesostriatal function.
SUMMARY: Abnormalities in reward processing offer insights into the symptomatology of schizophrenia and its underlying neurobiology. Further investigation is required into the specificity of these deficits to particular symptom expression and to what extent they are improved by antipsychotic treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20051858     DOI: 10.1097/YCO.0b013e328336661b

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  36 in total

1.  Behavioral effects of phencyclidine on nicotine self-administration and reinstatement in the presence or absence of a visual stimulus in rats.

Authors:  Natashia Swalve; Steven T Pittenger; Rick A Bevins; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

2.  Do reward-processing deficits in schizophrenia-spectrum disorders promote cannabis use? An investigation of physiological response to natural rewards and drug cues.

Authors:  Clifford M Cassidy; Mathieu B Brodeur; Martin Lepage; Ashok Malla
Journal:  J Psychiatry Neurosci       Date:  2014-09       Impact factor: 6.186

3.  Functional lateralization of the anterior insula during feedback processing.

Authors:  Jakub Späti; Justin Chumbley; Janis Brakowski; Nadja Dörig; Martin Grosse Holtforth; Erich Seifritz; Simona Spinelli
Journal:  Hum Brain Mapp       Date:  2014-02-19       Impact factor: 5.038

4.  Functional dysconnectivity of the limbic loop of frontostriatal circuits in first-episode, treatment-naive schizophrenia.

Authors:  Pan Lin; Xiaosheng Wang; Bei Zhang; Brian Kirkpatrick; Dost Öngür; James J Levitt; Jorge Jovicich; Shuqiao Yao; Xiang Wang
Journal:  Hum Brain Mapp       Date:  2017-11-02       Impact factor: 5.038

5.  Ventral Striatal Dysfunction and Symptom Expression in Individuals With Schizotypal Personality Traits and Early Psychosis.

Authors:  Matthias Kirschner; Oliver M Hager; Larissa Muff; Martin Bischof; Matthias N Hartmann-Riemer; Agne Kluge; Benedikt Habermeyer; Erich Seifritz; Philippe N Tobler; Stefan Kaiser
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

6.  Improving temporal cognition by enhancing motivation.

Authors:  Billur Avlar; Julia B Kahn; Greg Jensen; Eric R Kandel; Eleanor H Simpson; Peter D Balsam
Journal:  Behav Neurosci       Date:  2015-08-10       Impact factor: 1.912

7.  Negative symptom improvement during cognitive rehabilitation: results from a 2-year trial of Cognitive Enhancement Therapy.

Authors:  Shaun M Eack; Raquelle I Mesholam-Gately; Deborah P Greenwald; Susan S Hogarty; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2013-04-23       Impact factor: 3.222

8.  Differential hedonic experience and behavioral activation in schizophrenia and bipolar disorder.

Authors:  Ivy F Tso; Tyler B Grove; Stephan F Taylor
Journal:  Psychiatry Res       Date:  2014-06-25       Impact factor: 3.222

9.  Reinforcement learning deficits in people with schizophrenia persist after extended trials.

Authors:  David C Cicero; Elizabeth A Martin; Theresa M Becker; John G Kerns
Journal:  Psychiatry Res       Date:  2014-08-15       Impact factor: 3.222

10.  The electrophysiological signature of motivational salience in mice and implications for schizophrenia.

Authors:  Carolin Moessnang; Ute Habel; Frank Schneider; Steven J Siegel
Journal:  Neuropsychopharmacology       Date:  2012-08-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.